• Je něco špatně v tomto záznamu ?

Pregnancy and pregnancy outcomes after hematopoietic stem cell transplantation in childhood: a cross-sectional survey of the EBMT Pediatric Diseases Working Party

T. Diesch-Furlanetto, A. Rovó, JE. Galimard, G. Szinnai, A. Dalissier, P. Sedlacek, I. Bodova, VK. Roussou, BE. Gibson, X. Poiré, F. Fagioli, H. Pichler, M. Faraci, FG. Gumy-Pause, JH. Dalle, A. Balduzzi, P. Bader, S. Corbacioglu

. 2021 ; 36 (11) : 2871-2882. [pub] 20211018

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003451

STUDY QUESTION: What are the characteristics of patients with conceptions transplanted in childhood and adolescence? SUMMARY ANSWER: Insemination and conception after hematopoietic stem cell transplantation (HCT) in childhood or adolescence was possible, even after myeloablative conditioning regimes, although some patients required reproductive medicine support. WHAT IS KNOWN ALREADY: Preparative regimens of HCT are highly gonadotoxic, which leads to gonadal failure and pubertal development disorders. There are few population-based studies assessing the risk of future infertility in children after HCT. STUDY DESIGN, SIZE, DURATION: We conducted a retrospective study to investigate natural or assisted conceptions and their outcomes in patients <18 years old before their first transplantation who received HCT between 1995 and 2016 and were in the European Society for Blood and Marrow Transplantation (EBMT) registry. Adoptions were excluded from the analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Detailed information concerning pregnancy occurrences and outcomes were obtained by a separate questionnaire. Quantitative variables were presented as medians with their interquartile range (IQR) or range, and categorical variables were presented as frequencies and percentages. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 62 988 pediatric patients received a first HCT in EBMT centers between 1995 and 2016. Pregnancy was reported in 406 patients in the database. The median age at transplantation was 15.7 (range: 0.7-18) years, and the median age at declared conception was 25.0 (range: 16.3-38.8) years. Details concerning the first pregnancy and pregnancy outcome were obtained from 99 patients (24%) from the returned questionnaires. The median age at delivery or pregnancy interruption of the females was 23.0 (IQR: 20.8-27) years, with a median time after transplant of 10.7 (IQR: 6.6-15.4) years. Compared with the mean age of healthy women at their first child's birth (29 years old), the transplanted women delivered 5 years earlier (mean: 24.3 years). In terms of conception modality, 13/25 (52%) females conditioned with total body irradiation (TBI) and 50/52 (96%) of those conditioned without TBI conceived naturally. All seven male patients who had been conditioned with TBI achieved fatherhood but required assisted fertilization or used their cryopreserved sperm. In the females, 63/70 (90%) of all conceptions resulted in a live birth, 49/63 (84.5%) were at term and 43/46 (93%) had normal birthweight. Cesarean delivery was performed in 9/61 (15%) especially in women who had received a myeloablative regimen. LIMITATIONS, REASONS FOR CAUTION: In the EBMT pediatric dataset, the age at last follow-up or death was <17 years for 75% of the patients, therefore a longer follow-up for all patients would be necessary to calculate the cumulative incidence of conception for patients transplanted during childhood and allow all patients to realize their reproductive willingness/potential. WIDER IMPLICATIONS OF THE FINDINGS: Reproductive health surveillance and fertility preservation counseling are important in younger transplanted patients. Our results showed that there is a window of opportunity to conceive naturally or with reproductive medicine support. STUDY FUNDING/COMPETING INTEREST(S): Funding was provided by the 'Stiftung für krebskranke Kinder Regio Basiliensis', Basel, Switzerland. All authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.

Clinica Pediatrica Università degli Studi di Milano Bicocca Ospedale San Gerardo Monza Italy

Department of Hematology and Central Hematology Laboratory Inselspital Bern University Hospital University of Bern Bern Switzerland

Department of Hematology Cliniques Universitaires St Luc Brussels Belgium

Department of Hematology Royal Hospital for Children Schiehallion Ward Glasgow UK

Department of Pediatric Hematology and Oncology University Hospital Motol Prague Czech Republic

Department of Pediatric Hematology Hôpital Robert Debré GH APHP Nord Université de Paris Paris France

Department of Pediatric Hematology Oncology and Stem Cell Transplantation University of Regensburg Regensburg Germany

Department of Pediatrics St Anna Kinderspital and Children's Cancer Research Institute Medical University of Vienna Vienna Austria

Dipartimento di Emato Oncologia Pediatrica Centro Trapianti Cellule Staminali Institute G Gaslini Genova Italy

Division of Pediatric Endocrinology Diabetology University Children's Hospital Basel UKBB University of Basel Basel Switzerland

Division of Pediatric Oncology and Hematology Department of Women Child and Adolescent University Hospital of Geneva University of Geneva Geneva Switzerland

Division of Pediatric Oncology Hematology University Children's Hospital Basel UKBB University of Basel Basel Switzerland

Division of Stem Cell Transplantation and Immunology Hospital for Children and Adolescents of Frankfurt Frankfurt Germany

EBMT Paris Study Office Paris France

Onco Ematologia Pediatrica Centro Trapianti Cellule Staminali Ospedale Infantile Regina Margherita Turin Italy

Pediatric University Teaching Hospital BMT Unit 2 Children's Clinic Bratislava Slovakia

St Sophia Children's Hospital Oncology Center MARIANNA 5 VARDINOGIANNIS ELPIDA BMT Unit Athens Greece

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003451
003      
CZ-PrNML
005      
20220127150223.0
007      
ta
008      
220113s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/humrep/deab199 $2 doi
035    __
$a (PubMed)34529796
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Diesch-Furlanetto, T $u Division of Pediatric Oncology/Hematology, University Children's Hospital Basel, UKBB, University of Basel, Basel, Switzerland
245    10
$a Pregnancy and pregnancy outcomes after hematopoietic stem cell transplantation in childhood: a cross-sectional survey of the EBMT Pediatric Diseases Working Party / $c T. Diesch-Furlanetto, A. Rovó, JE. Galimard, G. Szinnai, A. Dalissier, P. Sedlacek, I. Bodova, VK. Roussou, BE. Gibson, X. Poiré, F. Fagioli, H. Pichler, M. Faraci, FG. Gumy-Pause, JH. Dalle, A. Balduzzi, P. Bader, S. Corbacioglu
520    9_
$a STUDY QUESTION: What are the characteristics of patients with conceptions transplanted in childhood and adolescence? SUMMARY ANSWER: Insemination and conception after hematopoietic stem cell transplantation (HCT) in childhood or adolescence was possible, even after myeloablative conditioning regimes, although some patients required reproductive medicine support. WHAT IS KNOWN ALREADY: Preparative regimens of HCT are highly gonadotoxic, which leads to gonadal failure and pubertal development disorders. There are few population-based studies assessing the risk of future infertility in children after HCT. STUDY DESIGN, SIZE, DURATION: We conducted a retrospective study to investigate natural or assisted conceptions and their outcomes in patients <18 years old before their first transplantation who received HCT between 1995 and 2016 and were in the European Society for Blood and Marrow Transplantation (EBMT) registry. Adoptions were excluded from the analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: Detailed information concerning pregnancy occurrences and outcomes were obtained by a separate questionnaire. Quantitative variables were presented as medians with their interquartile range (IQR) or range, and categorical variables were presented as frequencies and percentages. MAIN RESULTS AND THE ROLE OF CHANCE: In total, 62 988 pediatric patients received a first HCT in EBMT centers between 1995 and 2016. Pregnancy was reported in 406 patients in the database. The median age at transplantation was 15.7 (range: 0.7-18) years, and the median age at declared conception was 25.0 (range: 16.3-38.8) years. Details concerning the first pregnancy and pregnancy outcome were obtained from 99 patients (24%) from the returned questionnaires. The median age at delivery or pregnancy interruption of the females was 23.0 (IQR: 20.8-27) years, with a median time after transplant of 10.7 (IQR: 6.6-15.4) years. Compared with the mean age of healthy women at their first child's birth (29 years old), the transplanted women delivered 5 years earlier (mean: 24.3 years). In terms of conception modality, 13/25 (52%) females conditioned with total body irradiation (TBI) and 50/52 (96%) of those conditioned without TBI conceived naturally. All seven male patients who had been conditioned with TBI achieved fatherhood but required assisted fertilization or used their cryopreserved sperm. In the females, 63/70 (90%) of all conceptions resulted in a live birth, 49/63 (84.5%) were at term and 43/46 (93%) had normal birthweight. Cesarean delivery was performed in 9/61 (15%) especially in women who had received a myeloablative regimen. LIMITATIONS, REASONS FOR CAUTION: In the EBMT pediatric dataset, the age at last follow-up or death was <17 years for 75% of the patients, therefore a longer follow-up for all patients would be necessary to calculate the cumulative incidence of conception for patients transplanted during childhood and allow all patients to realize their reproductive willingness/potential. WIDER IMPLICATIONS OF THE FINDINGS: Reproductive health surveillance and fertility preservation counseling are important in younger transplanted patients. Our results showed that there is a window of opportunity to conceive naturally or with reproductive medicine support. STUDY FUNDING/COMPETING INTEREST(S): Funding was provided by the 'Stiftung für krebskranke Kinder Regio Basiliensis', Basel, Switzerland. All authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a dítě $7 D002648
650    _2
$a průřezové studie $7 D003430
650    _2
$a ženské pohlaví $7 D005260
650    12
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a narození živého dítěte $7 D050498
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a těhotenství $7 D011247
650    12
$a výsledek těhotenství $7 D011256
650    _2
$a retrospektivní studie $7 D012189
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Rovó, A $u Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
700    1_
$a Galimard, J E $u EBMT Paris Study Office, Paris, France
700    1_
$a Szinnai, G $u Division of Pediatric Endocrinology/Diabetology, University Children's Hospital Basel, UKBB, University of Basel, Basel, Switzerland
700    1_
$a Dalissier, A $u EBMT Paris Study Office, Paris, France
700    1_
$a Sedlacek, P $u Department of Pediatric Hematology and Oncology, University Hospital Motol, Prague, Czech Republic
700    1_
$a Bodova, I $u Pediatric University Teaching Hospital, BMT Unit, II Children's Clinic, Bratislava, Slovakia
700    1_
$a Roussou, V K $u St. Sophia Children's Hospital, Oncology Center, "MARIANNA V. VARDINOGIANNIS-ELPIDA", BMT Unit, Athens, Greece
700    1_
$a Gibson, B E $u Department of Hematology, Royal Hospital for Children, Schiehallion Ward (Ward 2A), Glasgow, UK
700    1_
$a Poiré, X $u Department of Hematology, Cliniques Universitaires St. Luc, Brussels, Belgium
700    1_
$a Fagioli, F $u Onco-Ematologia Pediatrica, Centro Trapianti Cellule Staminali, Ospedale Infantile Regina Margherita, Turin, Italy
700    1_
$a Pichler, H $u Department of Pediatrics, St. Anna Kinderspital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria
700    1_
$a Faraci, M $u Dipartimento di Emato-Oncologia Pediatrica, Centro Trapianti Cellule Staminali, Institute G. Gaslini, Genova, Italy
700    1_
$a Gumy-Pause, F G $u Division of Pediatric Oncology and Hematology, Department of Women, Child and Adolescent, University Hospital of Geneva, University of Geneva, Geneva, Switzerland
700    1_
$a Dalle, J H $u Department of Pediatric Hematology, Hôpital Robert Debré, GH APHP-Nord Université de Paris,Paris, France
700    1_
$a Balduzzi, A $u Clinica Pediatrica, Università degli Studi di Milano-Bicocca, Ospedale San Gerardo, Monza, Italy
700    1_
$a Bader, P $u Division of Stem-Cell Transplantation and Immunology, Hospital for Children and Adolescents of Frankfurt, Frankfurt, Germany
700    1_
$a Corbacioglu, S $u Department of Pediatric Hematology, Oncology and Stem-Cell Transplantation, University of Regensburg, Regensburg, Germany
773    0_
$w MED00002081 $t Human reproduction (Oxford, England) $x 1460-2350 $g Roč. 36, č. 11 (2021), s. 2871-2882
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34529796 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150220 $b ABA008
999    __
$a ok $b bmc $g 1751030 $s 1154600
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 36 $c 11 $d 2871-2882 $e 20211018 $i 1460-2350 $m Human reproduction $n Hum. reprod. (Oxf., Print) $x MED00002081
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...